



IV MANUAL & AGILIA DRUG LIBRARY UPDATE

CHANGES EFFECTIVE JULY 17, 2026

For distribution by:

Pharmacy
Executive Directors (Operations)
Executive Directors (Medical)

For the information of:

Pharmacy Staff
Nursing Staff
Medical Staff

Contact for Pump issues:

smartpumps@nshealth.ca

Contact for IV Manual issues

Theresa.Hurley@nshealth.ca

The Nova Scotia Health IV Manual website is being updated
Dataset will be uploaded to Agilia smart pumps July 17, 2026

The following table summarizes major changes

Pump Library Affected	Pump Change	IV Manual Change	Drug (date posted; date of update unless otherwise specified) Major Changes
None	None	IV direct removed	Ampicillin (July 3, 2026) IV direct instructions removed. Majority of adult doses are 2 g necessitating IV direct administration over 20 minutes. Technically does not meet the definition of IV direct and is not practical.
Oncology supportive	New therapy	New drug	Anakinra New monograph
None	None	Removed 100 mg/mL vials Dialysis circuit anticoagulation removed	Argatroban (April 21, 2026) No longer marketed in Canada. 1 mg/mL (50 mL) ready-to-use vial is standard preparation. Argatroban will no longer be used for dialysis circuit anticoagulation in NS Health.
None	None	IM reconstitution clarified	Ceftriaxone (April 15, 2026) In miscellaneous section, IM reconstitution instructions include information for reconstituting to 350 mg/mL only.
None	None	Alternative treatment clarified	Danaparoid (March 24, 2026) Clarification in dosage section that argatroban is preferred for systemic therapeutic anticoagulation in patients with renal impairment since it does not require adjustments for renal dysfunction.
Critical Care Medical/Surgical	New therapy	New drug	Doxycycline (May 4, 2026) New monograph
None	None	New indication added	Glucagon Indication and dose for epinephrine refractory anaphylaxis added.

IV MANUAL & AGILIA DRUG LIBRARY UPDATE

None	None	Option for IV direct loading dose prior to continuous infusion removed	Heparin (July 3, 2026) Statement in dosing section for IV direct loading dose prior to a continuous infusion removed. Not an option in OPOR– Clinical Information System. IV direct administration remains in the monograph for other uses (e.g., dialysis, organ donors, loading dose without continuous infusion).
None	None	Special access status removed	Imipenem–Cilastatin–Relebactam (July 3, 2026) This drug is no longer a Special Access Program medication. Statement removed from monograph.
None	None	Preparation of a 50 mcg/mL IV bag added	Isoproterenol (June 18, 2026) Information added to compatibility/stability section on how to prepare a 50 mcg/mL IV bag pending adoption of an official alternate concentration.
None	None	Acceptable tubing specified	Letermovir (June 18, 2026) Acceptable administration sets detailed. Drug is incompatible with polyurethane.
None	None	New drug	Meropenem–Vaborbactam (May 19, 2026) New monograph
Antidote Critical Care Medical/Surgical Oncology Supportive	VTBI revised	Preparation of continuous infusion clarified	Octreotide Continuous infusion must be prepared using octreotide 500 mcg/mL (1 mL). This ensures a consistent volume to be infused (VTBI) and administration rate (mL/h) between Agilia pumps and OPOR–Clinical Information System.
None	None	Reconstitution instructions clarified	Penicillin G Sodium (April 21, 2026) Reconstitution instructions clarified. Currently one manufacturer in Canada. Instructions aligned with OPOR–Clinical Information System and NS Health Central Intravenous Admixture Program.
None	None	Preparation of continuous infusion added	Piperacillin Tazobactam (June 18, 2026) Special reconstitution and preparation instructions added to continuous infusion column. A “continuous infusion” is simulated by hanging sequential IV bags.
None	None	Stability of continuous infusion revised	Vasopressin (July 3, 2026) Importing US product secondary to Canadian drug shortage. Stability revised.

IV MANUAL & AGILIA DRUG LIBRARY UPDATE

Hazardous Medications

The following IV medications are identified as hazardous in the ALERTS section of the IV monograph consistent with “Identification and Safe Handling of Hazardous Drugs (and Associated Contaminated Materials)” policy. Refer to policy for details; link below.

https://policy.nshealth.ca/Site_Published/NSHA/document_render.aspx?documentRender.IdType=6&documentRender.GenericField=&documentRender.Id=112664

cidofovir	etoposide	Pamidronate
clevidipine	fluconazole	phenytoin
cyclophosphamide	foscarnet	tacrolimus
cycloSPORINE	ganciclovir	valproic acid
dexmedetomidine	isavuconazole	voriconazole
dextrazoxane	methotrexate	zidovudine
dihydroergotamine	mitoxantrone	zoledronic acid
ergonovine	mycophenolate	
estrogens–conjugated	paclitaxel	